O receptor ativado por protease do tipo 1 (PAR1) parece estar associado ao reparo periodontal, enquanto o tipo 2 (PAR2) com a inflamação periodontal. Esses receptores podem ser ativados pelas proteases gingipaina, uma protease secretada pela Porphyromonas gingivalis, um importante periodontopatógeno, e pela proteinase-3 de neutrófilos (P3), que é liberada por neutrófilos quando expostos a um estímulo inflamatório. Uma vez que o diabetes é reconhecido como um fator de risco importante para a doença periodontal, o objetivo deste estudo foi investigar a expressão de PAR1 e de PAR2 e de seus ativadores, gingipaina e P3 no fluido gengival (FG) de pacientes diabéticos com periodontite crônica, antes e após tratamento periodontal não cirúrgico. Amostras de FG e os parâmetros clínicos, como profundidade de sondagem (PS), nível clínico de inserção (NCI), sangramento à sondagem (SS) e índice de placa (IP) foram coletados de pacientes sistemicamente saudáveis e de pacientes com diabetes mellitus do tipo 2 (DMT2) com periodontite crônica , no baseline e após o tratamento periodontal não cirúrgico. As expressões gênicas de PAR1, PAR2, gingipaina e P3 no FG foram quantificadas por qPCR. Os parâmetros clínicos melhoraram significativamente após a terapia periodontal (p <0,01). O diabetes levou ao aumento da expressão de PAR1 no fluido gengival e na presença da periodontite crônica diminuiu significativamente a expressão de PAR1, PAR2 e P3 (p<0,05). Além disso, o tratamento periodontal não cirúrgico em diabéticos resultou no aumento da expressão de PAR1 e de PAR2 (p<0,05). Dentro dos limites do presente estudo, sugerimos que os PARs podem estar associados com a inflamação periodontal em diabéticos. / Protease activated receptor type 1 (PAR1) seems to play a role in periodontal repair, while PAR2 is associated with periodontal inflammation. These receptors can be activated by gingipain, a protease released from Porphyromonas gingivalis, an important periodontal pathogen, and neutrophil proteinase-3 (P3), which is released by neutrophils when exposed to an inflammatory stimulus. Since diabetes is known risk factor to periodontal disease, the aim of this study was to investigate PAR1 and PAR2 mRNA expression at the gingival crevicular fluid (GCF) in diabetic patients with chronic periodontitis, before and after non-surgical periodontal treatment. GCF samples and clinical parameters consisting of measuring probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP) and plaque index (PI) were collected from systemically healthy patients and patients with type 2 diabetes mellitus with chronic periodontitis, at baseline and after nonsurgical periodontal treatment. PAR1 and PAR2, as well the expression of the activators gingipain and P3 at the GCF were quantified by qPCR. The clinical parameters improved significantly after periodontal therapy (p <0.01). Diabetes led to increased expression of PAR1 in the GCF, and the presence of chronic periodontitis significantly decreased the expression of PAR1, PAR2 and P3 (p <0.05). Moreover, non-surgical periodontal treatment in diabetics resulted in increased expression of PAR1 and PAR2 (p <0.05). Within the limits of this study, we suggest that PARs may be associated with periodontal inflammation in diabetics.

O receptor ativado por protease do tipo 1 (PAR1) parece estar associado ao reparo periodontal, enquanto o tipo 2 (PAR2) com a inflamação periodontal. Esses receptores podem ser ativados pelas proteases gingipaina, uma protease secretada pela Porphyromonas gingivalis, um importante periodontopatógeno, e pela proteinase-3 de neutrófilos (P3), que é liberada por neutrófilos quando expostos a um estímulo inflamatório. Uma vez que o diabetes é reconhecido como um fator de risco importante para a doença periodontal, o objetivo deste estudo foi investigar a expressão de PAR1 e de PAR2 e de seus ativadores, gingipaina e P3 no fluido gengival (FG) de pacientes diabéticos com periodontite crônica, antes e após tratamento periodontal não cirúrgico. Amostras de FG e os parâmetros clínicos, como profundidade de sondagem (PS), nível clínico de inserção (NCI), sangramento à sondagem (SS) e índice de placa (IP) foram coletados de pacientes sistemicamente saudáveis e de pacientes com diabetes mellitus do tipo 2 (DMT2) com periodontite crônica , no baseline e após o tratamento periodontal não cirúrgico. As expressões gênicas de PAR1, PAR2, gingipaina e P3 no FG foram quantificadas por qPCR. Os parâmetros clínicos melhoraram significativamente após a terapia periodontal (p <0,01). O diabetes levou ao aumento da expressão de PAR1 no fluido gengival e na presença da periodontite crônica diminuiu significativamente a expressão de PAR1, PAR2 e P3 (p<0,05). Além disso, o tratamento periodontal não cirúrgico em diabéticos resultou no aumento da expressão de PAR1 e de PAR2 (p<0,05). Dentro dos limites do presente estudo, sugerimos que os PARs podem estar associados com a inflamação periodontal em diabéticos. / Protease activated receptor type 1 (PAR1) seems to play a role in periodontal repair, while PAR2 is associated with periodontal inflammation. These receptors can be activated by gingipain, a protease released from Porphyromonas gingivalis, an important periodontal pathogen, and neutrophil proteinase-3 (P3), which is released by neutrophils when exposed to an inflammatory stimulus. Since diabetes is known risk factor to periodontal disease, the aim of this study was to investigate PAR1 and PAR2 mRNA expression at the gingival crevicular fluid (GCF) in diabetic patients with chronic periodontitis, before and after non-surgical periodontal treatment. GCF samples and clinical parameters consisting of measuring probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP) and plaque index (PI) were collected from systemically healthy patients and patients with type 2 diabetes mellitus with chronic periodontitis, at baseline and after nonsurgical periodontal treatment. PAR1 and PAR2, as well the expression of the activators gingipain and P3 at the GCF were quantified by qPCR. The clinical parameters improved significantly after periodontal therapy (p <0.01). Diabetes led to increased expression of PAR1 in the GCF, and the presence of chronic periodontitis significantly decreased the expression of PAR1, PAR2 and P3 (p <0.05). Moreover, non-surgical periodontal treatment in diabetics resulted in increased expression of PAR1 and PAR2 (p <0.05). Within the limits of this study, we suggest that PARs may be associated with periodontal inflammation in diabetics.

Protease-Activated Receptors (PARs) belong to an unusual family of G Protein Coupled Receptors (GPCRs). Each of the four known members is activated by its own N-terminus exposed by proteolytic cleavage and there is no other endogenous agonist known to date. PAR2 is the second member of the family and it has been implicated in wide range of pathophysiological conditions, particularly in various inflammatory diseases and cancers. In contrast, very little is known about the PAR2 receptor itself despite having been discovered more than 10 years ago. The purpose of this project was to improve our understanding of PAR2 regulation by discovering new agonists and antagonists and using them to probe the structural and functional properties of the receptor. Chapter 1 provides a brief literature overview of the initial discovery of PAR2, what is known about the mechanism of receptor activation, information on the structures and properties of current agonists and an antagonist for PAR2, and the putative physiological roles of human PAR2. As well, it summarizes the aims of this thesis. Chapter 2 investigates the regulation of gene expression by two different agonists of PAR2, a synthetic hexapeptide, 2f-LIGRLO-NH2, and the endogenous activator, trypsin, the idea being that genes up- or down- regulated by both agonists may more accurately profile PAR2-selective events. The effects of PAR2 activation on gene transcription in the human kidney HEK293 cell line were studied using a DNA microarray consisting of 19,000 human genes in an attempt to broadly cover the human genome and associated cell pathways with PAR2 activation. About 2,500 genes were regulated similarly by both agonists and, for genes expressed more than 5-fold, the mRNA results were further analyzed by quantitative RT-PCR techniques. PAR2 activation was shown to be associated with cellular metabolism, cell cycle, mitogen-activated protein kinase pathways, histone deacetylase and sirtuin enzymes, inflammatory cytokines and anti-complement function. Chapter 3 described a range of molecular events surrounding the activation of the receptor. PAR2 mRNA expression was quantitated by qRT-PCR and cross-checked with an intracellular Ca2+ assay. In this way whole cell PAR2 could be correlated with cell surface expression of PAR2. Three cell lines expressing high levels of PAR2 were chosen for subsequent experiments, these being colorectal carcinoma HT29, lung carcinoma A549 and human embryonic kidney HEK293 cells. Receptor activation, internalization, desensitization and resensitization assays were carried out on these cell lines to define some key functions relevant for investigating inhibitors in subsequent chapters. Chapter 4 reports a PAR2 mutagenesis study designed to identify the location of the binding site on PAR2 for a specific peptide agonist. A homology model of PAR2 based on bovine rhodopsin was used for docking of an agonist ligand, and the docking results were then investigated via two successive rounds of PAR2 mutagenesis in which the effect of each mutation (20 in all) was separately investigated by changes in agonist potency in the intracellular calcium release assay. Five PAR2 mutants showed more than a 5-fold reduction in agonist potency, while three others showed up to a 7-fold reduction. Mutations found to be important for agonist activity were mapped back to the model. Because there was extensive clustering of these key mutated amino acids, it is likely that this study has pinpointed the precise binding site of the agonist peptide in PAR2. Interestingly, this site is within the transmembrane region of the receptor. Chapter 5 reports the design, discovery and development of novel PAR2 agonists and antagonists and their regulatory effects in a diverse array of cell types. Structure-activity relationships were used to examine influences on the first, sixth and seventh positions of a PAR2 agonist peptide. At least five compounds were found herein to be equiopotent with the most potent PAR2 agonist reported. Knowledge obtained from this study was then used to create the first non-peptidic agonists for PAR2. The most potent nonpeptidic agonist (retaining one natural amino acid) was at least equipotent with the best peptide agonists. Conversion to nonpeptidic antagonists proved to be successful and this chapter reports the most potent known nonpeptide antagonist, which was selective for PAR2 and active at low micromolar concentrations. It inhibited intracellular Ca2+ release induced by different PAR2 agonists (trypsin, 2f-LIGRLO-NH2, nonpeptide agonists) in multiple cell lines (HT29, Panc-1, A549, MKN1, MKN45, MDA-MB-231, HUVEC) that have been physiologically associated with PAR2. It also inhibited release of inflammatory cytokines IL-8 and IL-6 and shows antiproliferative activity against primary human cells. The antagonist is competitive, reversible and surmountable (pA2 6.11). This thesis summarizes a large body of work that provides valuable molecular insights to PAR2 regulation, and lays the groundwork for rational design and development of novel nonpeptidic agonists and antagonists of PAR2 as potentially valuable pharmacological probes in vivo and as useful leads to development of therapeutics for inflammatory diseases and cancers.

O peptídeo idêntico ao C-terminal da proteína S100A9 murina (pS100A9mH92-G110) inibe a hiperalgesia inflamatória induzida pela carragenina. Em adição, este peptídeo inibe a hiperalgesia inflamatória induzida por tripsina, uma serino protease capaz de ativar receptores ativados por protease do tipo 2 (PAR2). O objetivo inicial deste trabalho foi caracterizar a relação estrutura/ efeito do pS100A9m, a fim de determinar a menor seqüência peptídica dotada de atividade antinociceptiva. Ainda, como parte dos objetivos, neste trabalho foram investigados os mecanismos envolvidos no efeito antinociceptivo do pS100A9m e da menor seqüência ativa sobre a hiperalgesia induzida pela ativação de PAR2. Diferentes seqüências peptídicas homólogas ao pS100A9m foram sintetizadas e avaliadas em ratos submetidos ao modelo de hiperalgesia mecânica induzida por carragenina. Dentre todas as seqüências peptídicas investigadas, o peptídeo denominado AcE97-G102 foi determinado como a menor seqüência ativa com efeito semelhante ao pS100A9m. Com relação aos estudos sobre a ativação de PAR2, os resultados obtidos demonstraram que o pS100A9m bem como o AcE97-G102 inibem a hiperalgesia térmica e mecânica decorrentes da ativação de PAR2 (induzida por um peptídeo agonista deste receptor ? PAR2AP). A análise por imuno-histoquímica demonstrou que a ativação de PAR2 aumenta a expressão da proteína Egr-1 em neurônios nociceptivos, sendo o pS100A9m capaz de inibir este efeito. Em adição, ambos pS100A9m e AcE97-G102 inibiram o influxo de cálcio induzido por PAR2AP ou tripsina, em neurônios sensoriais do gânglio da raiz dorsal da medula espinhal (DRG). Por outro lado, nenhum dos peptídeos apresentou efeito sobre a mobilização de cálcio em células HEK-293, que naturalmente expressam PAR2, ou em células KNRK transfectadas com este tipo de receptor, sugerindo que o efeito tanto do pS100A9m quanto do AcE97-G102, sobre a ativação de PAR2, seja específico para neurônios sensoriais. O pS100A9m e o AcE97-G102 inibiram o influxo de cálcio nos neurônios DRG estimulados com bradicinina, capsaicina ou KCl. Ainda, o pS100A9m inibiu a liberação de substância P induzida por PAR2. Os resultados obtidos com o tratamento de neurônios DRG com tapsigaragina ou com ionóforo de cálcio sugerem um efeito direto do pS100A9m sobre os canais de cálcio. Desta forma, foi avaliada atividade do pS100A9m e do AcE97-G102 sobre culturas de células HEK-tsA transfectadas com canais de cálcio dependente de voltagem do tipo N ou do tipo L. Os resultados obtidos demonstraram que ambos peptídeos inibirem o influxo de cálcio em células transfectadas com receptores do tipo N. Em conjunto, os dados aqui obtidos demonstram que o efeito do C-terminal da proteína S100A9 murina sobre a nocicepção experimental é devido a uma inibição de canais de cálcio do tipo N, por uma ação direta em neurônios sensoriais. Ainda, a seqüência responsável por este efeito está localizada na porção E97-G102 do domínio C-terminal da proteína S100A9 murina. / Peptide identical to the C-terminus of S100A9 protein (mS100A9pH92-G110) inhibits inflammatory hyperalgesia induced by carrageenan and trypsin, a serine protease that activates protease-activated receptors 2 (PAR2). The aim of this work was to characterize the relationship between structure and function of mS100A9p in order to identify the shortest peptide sequence endowed with antinociceptive effect. Furthermore, the mechanisms involved on the antinociceptive effect of both mS100A9p and the shortest homologous sequence on PAR2-induced hyperalgesia were also evaluated. Different peptide sequences homologous to mS100A9p were synthesized and evaluated in rats submitted to the carrageenan-induced mechanical hyperalgesia model. Among all evaluated sequences, the peptide AcE97-G102 was found to be the shortest sequence that showed an antinociceptive effect similar to that induced by mS100A9p. In regard to PAR2 activation, data obtained herein demonstrated that both mS100A9p and AcE97-G102 inhibit PAR2-induced mechanical and thermal hyperalgesia, induced by the selective agonist peptide ? PAR2AP. Imunohistochemical evaluation demonstrated that PAR2 activation increased Egr-1 protein expression on sensory neurons and mS100A9p inhibited this effect. In addition, both mS100A9p and AcE97-G102 inhibited PAR2- and trypsin-induced calcium influx in dorsal root ganglia neurons (DRG). On the other hand, no effect on the calcium influx of the peptides were observed on HEK-293 cells or KNRK-PAR2 transfected cells, suggesting that the effects of mS100A9p and AcE97-G102 on PAR2 activation are specific for sensory neurons. Both mS100A9p and AcE97-G102 inhibited DRG calcium flux when cells were stimulated with bradykinin, capsaicin or KCl. Also, mS100A9p inhibited PAR2-induced substance P release in DRG. Treatment of DRG with either thapsigargin or calcium ionophore suggest a direct effect of mS100A9p on calcium channels. To evaluate this hypothesis the effects of mS100A9p and AcE97-G102 were evaluated on N-type or L-type voltage-dependent calcium channel transfected HEK-tsA cells. Both peptides inhibited calcium influx of N-type transfected cells. In conclusion, data presented herein demonstrate that the C-terminus of murine S100A9 protein inhibits experimental nociception through a block of N-type voltage-dependent calcium channels, directly on sensory neurons. Also, the domain involved in this effect is localized on the sequence E97-G102 of the C-terminus of murine S100A9 protein.

O peptídeo idêntico ao C-terminal da proteína S100A9 murina (pS100A9mH92-G110) inibe a hiperalgesia inflamatória induzida pela carragenina. Em adição, este peptídeo inibe a hiperalgesia inflamatória induzida por tripsina, uma serino protease capaz de ativar receptores ativados por protease do tipo 2 (PAR2). O objetivo inicial deste trabalho foi caracterizar a relação estrutura/ efeito do pS100A9m, a fim de determinar a menor seqüência peptídica dotada de atividade antinociceptiva. Ainda, como parte dos objetivos, neste trabalho foram investigados os mecanismos envolvidos no efeito antinociceptivo do pS100A9m e da menor seqüência ativa sobre a hiperalgesia induzida pela ativação de PAR2. Diferentes seqüências peptídicas homólogas ao pS100A9m foram sintetizadas e avaliadas em ratos submetidos ao modelo de hiperalgesia mecânica induzida por carragenina. Dentre todas as seqüências peptídicas investigadas, o peptídeo denominado AcE97-G102 foi determinado como a menor seqüência ativa com efeito semelhante ao pS100A9m. Com relação aos estudos sobre a ativação de PAR2, os resultados obtidos demonstraram que o pS100A9m bem como o AcE97-G102 inibem a hiperalgesia térmica e mecânica decorrentes da ativação de PAR2 (induzida por um peptídeo agonista deste receptor ? PAR2AP). A análise por imuno-histoquímica demonstrou que a ativação de PAR2 aumenta a expressão da proteína Egr-1 em neurônios nociceptivos, sendo o pS100A9m capaz de inibir este efeito. Em adição, ambos pS100A9m e AcE97-G102 inibiram o influxo de cálcio induzido por PAR2AP ou tripsina, em neurônios sensoriais do gânglio da raiz dorsal da medula espinhal (DRG). Por outro lado, nenhum dos peptídeos apresentou efeito sobre a mobilização de cálcio em células HEK-293, que naturalmente expressam PAR2, ou em células KNRK transfectadas com este tipo de receptor, sugerindo que o efeito tanto do pS100A9m quanto do AcE97-G102, sobre a ativação de PAR2, seja específico para neurônios sensoriais. O pS100A9m e o AcE97-G102 inibiram o influxo de cálcio nos neurônios DRG estimulados com bradicinina, capsaicina ou KCl. Ainda, o pS100A9m inibiu a liberação de substância P induzida por PAR2. Os resultados obtidos com o tratamento de neurônios DRG com tapsigaragina ou com ionóforo de cálcio sugerem um efeito direto do pS100A9m sobre os canais de cálcio. Desta forma, foi avaliada atividade do pS100A9m e do AcE97-G102 sobre culturas de células HEK-tsA transfectadas com canais de cálcio dependente de voltagem do tipo N ou do tipo L. Os resultados obtidos demonstraram que ambos peptídeos inibirem o influxo de cálcio em células transfectadas com receptores do tipo N. Em conjunto, os dados aqui obtidos demonstram que o efeito do C-terminal da proteína S100A9 murina sobre a nocicepção experimental é devido a uma inibição de canais de cálcio do tipo N, por uma ação direta em neurônios sensoriais. Ainda, a seqüência responsável por este efeito está localizada na porção E97-G102 do domínio C-terminal da proteína S100A9 murina. / Peptide identical to the C-terminus of S100A9 protein (mS100A9pH92-G110) inhibits inflammatory hyperalgesia induced by carrageenan and trypsin, a serine protease that activates protease-activated receptors 2 (PAR2). The aim of this work was to characterize the relationship between structure and function of mS100A9p in order to identify the shortest peptide sequence endowed with antinociceptive effect. Furthermore, the mechanisms involved on the antinociceptive effect of both mS100A9p and the shortest homologous sequence on PAR2-induced hyperalgesia were also evaluated. Different peptide sequences homologous to mS100A9p were synthesized and evaluated in rats submitted to the carrageenan-induced mechanical hyperalgesia model. Among all evaluated sequences, the peptide AcE97-G102 was found to be the shortest sequence that showed an antinociceptive effect similar to that induced by mS100A9p. In regard to PAR2 activation, data obtained herein demonstrated that both mS100A9p and AcE97-G102 inhibit PAR2-induced mechanical and thermal hyperalgesia, induced by the selective agonist peptide ? PAR2AP. Imunohistochemical evaluation demonstrated that PAR2 activation increased Egr-1 protein expression on sensory neurons and mS100A9p inhibited this effect. In addition, both mS100A9p and AcE97-G102 inhibited PAR2- and trypsin-induced calcium influx in dorsal root ganglia neurons (DRG). On the other hand, no effect on the calcium influx of the peptides were observed on HEK-293 cells or KNRK-PAR2 transfected cells, suggesting that the effects of mS100A9p and AcE97-G102 on PAR2 activation are specific for sensory neurons. Both mS100A9p and AcE97-G102 inhibited DRG calcium flux when cells were stimulated with bradykinin, capsaicin or KCl. Also, mS100A9p inhibited PAR2-induced substance P release in DRG. Treatment of DRG with either thapsigargin or calcium ionophore suggest a direct effect of mS100A9p on calcium channels. To evaluate this hypothesis the effects of mS100A9p and AcE97-G102 were evaluated on N-type or L-type voltage-dependent calcium channel transfected HEK-tsA cells. Both peptides inhibited calcium influx of N-type transfected cells. In conclusion, data presented herein demonstrate that the C-terminus of murine S100A9 protein inhibits experimental nociception through a block of N-type voltage-dependent calcium channels, directly on sensory neurons. Also, the domain involved in this effect is localized on the sequence E97-G102 of the C-terminus of murine S100A9 protein.

Le mécanisme qui sous-tend la réponse inflammatoire en cas de défaut de la barrière épidermique reste à élucider. Dans cette étude, nous montrons qu’en cas de rupture de la barrière formée par le stractum corneum épidermal, une réponse inflammatoire mixte de type 17 et 2 est induite. Nous décrivons ici une régulation réciproque entre les axes cytokiniques IL-23/IL-17/IL-22 et TSLP/IL-4 qui conditionne l’apparition du phénotype inflammatoire au niveau cutané. Par ailleurs, nous démontrons également que la flore bactérienne présente à la surface de la peau est engagée dans l’induction de l’IL-23 et de la réponse de type 17 alors que le PAR2 stimule, quant à lui, l’expression de TSLP et à la réponse de type 2. Nos résultats montrent donc la complexité et l’hétérogénéité des réponses inflammatoires en conditions de rupture de la barrière cutanée et ont des implications au niveau des thérapies pour les maladies inflammatoires de la peau. / Dysfunction of the epidermal barrier has been recognized as a critical factor in the development of skin inflammation; yet, the mechanism underlying the inflammatory responses triggered by epidermal defects remains still elusive. Here, by employing mice with corneodesmosin (CDSN) gene ablated in keratinocytes, we show that upon the breakdown of the epidermal barrier, type 17 and type 2 inflammatory responses are co-induced in the skin. Furthermore, we delineate a counter-regulation between IL-23/IL-17/IL-22 and TSLP/IL-4 cytokine axes, which shapes the outcome of the inflammatory phenotype in skin. Moreover, we show that the bacteria skin flora are engaged in the induction of IL-23 and the type 17 response, whereas the protease activation receptor PAR2 mediates TSLP expression and the type 2 response. Our results shed light on the complexity and heterogeneity of inflammatory responses in barrier-defective skin, and have implications for treating skin inflammatory diseases.

Previous studies have shown that fish release alarming substances into the water to alert their kin to escape from danger. In our laboratory, we found that zebrafish produce trypsin and release it from their gills into the environment when they are under stress. By placing the zebrafish larvae in the middle of a small tank and then placing trypsin at one end of the tank, we observed that the larvae moved away from the trypsin zone and almost to the opposite end of the tank. This escape response was significant and did not occur in response to the control substances, bovine serum albumin (BSA), Russell's viper venom (RVV), and collagen. Also, previously, we had shown that the trypsin could act via a protease-activated receptor-2 (PAR2) on the surface of the cells. Therefore, we hypothesized that trypsin would induce a change in neuronal activity in the brain via PAR2-mediated signaling in cells on the surface of the fish body. To investigate whether the trypsin-responsive cells were surface cells, we generated a primary cell culture of zebrafish keratinocytes, confirmed these cells' identity by specific marker expression, and then incubated these cells with the calcium indicator Fluo-4 and exposed them to trypsin. By using calcium flux assay in a flow-cytometer, we found that trypsin-treated keratinocytes showed an increase in intracellular calcium release. To test whether PAR2 mediates the escape response to trypsin, we treated larvae with a PAR2 antagonist and showed that the trypsin-initiated escape response was abrogated. Furthermore, par2a mutants with knockdown of par2a by the piggyback knockdown method failed to respond to trypsin. Trypsin treatment of adult fish led to an approximately 2-fold increase in brain c-fos mRNA levels 45 mins after trypsin treatment, suggesting that trypsin signals may have reached the brain, probably via a spinothalamic pathway. Taken together, our results reveal a novel trypsin-initiated escape response in fish. These studies should enhance our understanding of fish communication in general and alarm behavior in particular. Furthermore, since pain receptors in other animals are also PAR2, our finding may be useful in exploring pathways of pain reception.

Breast cancer is the most common cancer type with a high annual death rate. Finding meaningful tissue-related or body-fluid-accessible biomarkers is necessary to characterize cancer subtype, predict tumor behavior, choose the most effective therapy, predict severe treatment-related toxicities, and also the opportunity to personalize treatments for each patient. There is increasing evidence that various kallikrein-related peptidases (Klk) gene family members can modulate the immune response and are differentially regulated in breast cancer, and therefore are proposed to be potential prognostic biomarkers. This work established and validated an experimental setup to study the roles of selected kallikrein-related peptidases (KLK5, KLK7, KLK14) in breast cancer in vivo using gene-deficient mouse models previously generated in our laboratory. We used the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) editing system to generate several E0771 cell line-based reporter and gene-deficient cell lines. These allowed enhanced monitoring of cancer progression in vivo and studying KLKs roles in tumor immune microenvironment of C57Bl/6N mice. Finally, we present the analysis of the initial in vivo experiments using these tools combined with established Klk-deficient mouse models. Our...

Background: Tissue factor (TF) is a 47 kDa transmembrane glycoprotein known as the main initiator of blood coagulation. TF is over-expressed on many malignant cells and apart from increasing the risk of thrombosis, the presence of TF/FVIIa also promotes the progression of cancer and metastasis by intracellular signaling. TF expressing microparticles (MP) are, moreover, often found in the circulation of cancer patients. Aim: The aim of this thesis was to study different aspects of TF activity, e.g. the importance of procoagulant MP and TF-induced intracellular signaling pathways, with focus on cell migration (chemotaxis) and apoptosis. Results: The TF signaling complexes were shown to prevent apoptosis induced by serum starvation and TRAIL in cancer cells by reduced activation of caspase-8 in a PI3k/AKT-dependent manner. FVIIa also decreased transcription of pro-apoptotic genes in cancer cells treated with TRAIL. Simvastatin triggered apoptosis by transcriptional reduction of BCL-2 due to cytosolic retention of NFκB. Simvastatin also inactivated the PI3k/AKT pathway and reduced the production of the MP-like prostasomes which, respectively, impaired the anti-apoptotic signaling by TF and reduced the procoagulant activity in the vicinity of prostate cancer cells. Intracellular events conducted by the TF/FVIIa complex selectively enhanced PDGF-BB induced chemotaxis which was partly explained by the TF/FVIIa-induced transactivation of the PDGFβ-receptor. This was dependent on Src-family members and engagement of PAR2. Conclusions: The results presented in this thesis extend the current knowledge of TF-mediated signaling. We report the TF complexes to govern the extrinsic pathway of apoptosis, present data on FVIIa-dependent regulation of apoptosis-related genes, and exclude known surface proteins as transmitters of the anti-apoptotic signals. We moreover describe TF/FVIIa to transactivate the PDGFβ-receptor and play a decisive role in the potentiated chemotaxis toward PDGF-BB in a number of cell types. Finally, we explain the mechanism behind simvastatin-induced apoptosis in cancer cells and how statins interfere with TF-dependent signaling and coagulation.